INmune Bio’s Alzheimer’s drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.
Alzheimer’s Setback Hits INmune Bio Stock, But FDA Hopes Remain
Where Today's News Shapes Tomorrow
February 13, 2026
Headlines
